

L8 ANSWER 81 OF 105 CAPLUS COPYRIGHT 2003 ACS
AN 1984:466008 CAPLUS
DN 101:66008
TI Modulating the immune response system in mammals
IN Lang, Stanley Albert, Jr.; Fields, Thomas Lynn; Wilkinson, Raymond George;
Kang, Soon Mok; Lin, Yank I.
PA American Cyanamid Co., USA
SO Eur. Pat. Appl., EP
CODEN: EPXXDE
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FI	EP 102476	A1	19840314	EP 1983-106543	19830705
	EP 102476	B1	19861105		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				

Patel

<5/3/2003>


US 4532349	A	19850730	US 1982-405666	19820806
AT 23268	E	19861115	US 1982-411399	19820825
JP 59046261	A2	19840315	US 1983-500715	19830603
ZA 8305783	A	19840425	US 1982-411399	19820825
ES 524772	A1	19850601	AT 1983-106543	19830705
CA 1215990	A1	19861230	US 1982-405666	19820806
CA 1230057	A2	19871208	US 1982-411399	19820825
			EP 1983-106543	19830705
			JP 1983-142664	19830805
			US 1982-405666	19820806
			US 1982-411399	19820825
			ZA 1983-5783	19830805
			US 1982-405666	19820806
			ES 1983-524772	19830805
			US 1982-405666	19820806
			US 1982-411399	19820825
			CA 1983-433977	19830805
			US 1982-405666	19820806
			US 1982-411399	19820825
			CA 1986-513549	19860710
			US 1982-405666	19820806
			US 1982-411399	19820825
			CA 1983-433977	19830805

OS CASREACT 101:66008

IT **80-08-0**RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of, with chloroacetyl chloride)


RN 80-08-0 CAPLUS

CN Benzenamine, 4,4'-sulfonylbis- (9CI) (CA INDEX NAME)

IT **80-02-4 565-20-8**RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(immune adjuvant activity of, neoplasm treatment in relation to)


RN 80-02-4 CAPLUS

CN Ethanol, 2-[[4-[(4-aminophenyl)sulfonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 565-20-8 CAPLUS


CN Acetamide, N-[4-[(4-aminophenyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

IT **32794-92-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and immune adjuvant activity of, neoplasm treatment in relation to)

RN 32794-92-6 CAPLUS


CN Acetamide, N,N'-(sulfonyldi-4,1-phenylene)bis[2-(methylamino)- (9CI) (CA INDEX NAME)

IT **17328-16-4P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and reaction with methylamine)

RN 17328-16-4 CAPLUS

CN Acetamide, N,N'-(sulfonyldi-4,1-phenylene)bis[2-chloro- (9CI) (CA INDEX NAME)



GI



I

AE The prepn. of N-substituted phenylthioanilines, phenylsulfinylanilines,

Patel

<5/3//2003>

and phenylsulfanylanilines I (R1 = H, Cl, or NO2; R2 = H or Cl; R3 = H, Br, Cl, F1, NO2, Cl-3 alkoxy, etc.; R4 and R5 = H or Cl; R6 = H or Cl-3 alkyl; R7 = H, Cl-3 alkyl, etc.; Z = S, SO, or SO2) is described for use as immune adjuvants. Some of the compds. were active in restoring antibody formation in mice with Rauscher virus-induced leukemia. The compds. may be useful for restoring immune function in **cancer**.


L8 ANSWER 21 OF 105 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:151752 CAPLUS
 DN 132:161237
 TI Chalone retinoids as antitumor agents
 IN Han, Rui; Guo, Zongru
 PA Institute of Materia Medica, Peop. Rep. China
 SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 19 pp.
 CODEN: CNXXEV
 DT Patent
 LA Chinese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1187185	A	19980708	CN 1996-194473	19960607
				CN 1996-194473	19960607


OS MARPAT 132:161237
 IT **258834-44-5**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (chalone retinoids as antitumor agents)
 RN 258834-44-5 CAPLUS
 CN Benzamide, N-[4-[4-(acetylamino)phenoxy]phenyl]-3,5-bis(1,1-dimethylethyl)-
 4-methoxy- (9CI) (CA INDEX NAME)

Patel

<5/3//2003>



GI



I

AB The chalone derivs. (I), R1-(3,5-di-t-butyl-1,4-phenylene)-CO-X-(1,4-phenylene)-CO-Z-(1,4-phenylene)-R4 (R1 = OH, or C1-5 alkoxy; R2 = OH, COOH, C1-5 carboxylalkyl, or NHCOR3; R3 = C1-4 alkyl; X = NH, or C2-4 alkenyl; and Z = NH, or O), are prepd. by dissolving chalone deriv. in anhyd. org. solvent, adding substituted amine and alkyl-haloformate (ester) in dropwise, stirring for 0.2-3.0 h, adding petroleum ether, filtering, concg. in vacuum, dissolving in anhyd. org. solvent, adding alkylphenol, heating to be clear, adding substituted amine and DMAP, stirring at 40-60.degree. for 0.5-3 h, concg., crystg., filtering, washing, and recrystg. with 90-99% ethanol. The medicinal compn. is composed of the chalone deriv., and medicinal carrier. The medicinal compn. may contain more than one anti-tumor drug and a immunoregulator. The medicinal compn. is used for treatment of **cancer**.

L8 ANSWER 81 OF 105 CAPLUS COPYRIGHT 2003 ACS
AN 1984:466008 CAPLUS
DN 101:66008
TI Modulating the immune response system in mammals
IN Lang, Stanley Albert, Jr.; Fields, Thomas Lynn; Wilkins, L. Raymond George;
Kang, Soon Mok; Lin, Yank I.
PA American Cyanamid Co., USA
SO Eur. Pat. Appl., 38 pp.
CODEN: EFXWDW
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO	DATE
PI	EP 102476	A1	19840314	EP 1983-106542	19830701
	EP 102476	B1	19861105		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				

Patel


<5/3//2003>

			US 1982-405666	19820806
			US 1982-411399	19820825
US 4532349	A	19850730	US 1983-500715	19830603
			US 1982-411399	19820825
AT 23268	E	19861115	AT 1983-106543	19830705
			US 1982-405666	19820806
			US 1982-411399	19820825
			EP 1983-106543	19830705
JP 59046261	A2	19840315	JP 1983-142664	19830805
			US 1982-405666	19820806
			US 1982-411399	19820825
ZA 8305783	A	19840425	ZA 1983-5783	19830805
			US 1982-405666	19820806
ES 524772	A1	19850601	ES 1983-524772	19830805
			US 1982-405666	19820806
			US 1982-411399	19820825
CA 1215990	A1	19861230	CA 1983-433977	19830805
			US 1982-405666	19820806
			US 1982-411399	19820825
CA 1230057	A2	19871208	CA 1986-513549	19860710
			US 1982-405666	19820806
			US 1982-411399	19820825
			CA 1983-433977	19830805


OS CASREACT 101:66008
 IT **80-08-0**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (acylation of, with chloroacetyl chloride)
 RN 80-08-0 CAPLUS
 CN Benzenamine, 4,4'-sulfonylbis- (9CI) (CA INDEX NAME)



IT **80-02-4 565-20-8**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (immune adjuvant activity of, neoplasm treatment in relation to)
 RN 80-02-4 CAPLUS
 CN Ethanol, 2-[[4-[(4-aminophenyl)sulfonyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 565-20-8 CAPLUS
 CN Acetamide, N-[4-[(4-aminophenyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

IT **32794-92-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and immune adjuvant activity of, neoplasm treatment in relation to)

RN 32794-92-6 CAPLUS


CN Acetamide, N,N'-(sulfonyldi-4,1-phenylene)bis[2-(methylamino)- (9CI) (CA INDEX NAME)

IT **17328-16-4P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. and reaction with methylamine)

RN 17328-16-4 CAPLUS

CN Acetamide, N,N'-(sulfonyldi-4,1-phenylene)bis[2-chloro- (9CI) (CA INDEX NAME)



GI



AB The prepn. of N-substituted phenylthioanilines, phenylsulfinylanilines,

Patel

<5/3//2003>

and phenylsulfanylanilines I (R1 = H, Cl, or NO2; R2 = H or Cl; R3 = H, Br, Cl, F1, NO2, Cl-3 alkoxy, etc.; R4 and R5 = H or Cl; R6 = H or Cl-3 alkyl; R7 = H, Cl-3 alkyl, etc.; Z = S, SO, or SO2) is described for use as immune adjuvants. Some of the compds. were active in restoring antibody formation in mice with Rauscher virus-induced leukemia. The compds. may be useful for restoring immune function in **cancer**.